(PharmaNewsWire.Com, April 23, 2018 ) The endometrium is the lining of the uterus. The majority of cancers that occur in the frame of the uterus (womb) are endometrial cancers. They are the 6th most common form of cancer in women globally (and the twelfth common cancer overall). Around 290,000 new cases were recorded in 2014, accounting for nearly 5% of all new cases of cancer in women (2 percent in average). Major incidences of endometrial cancers are recorded in North America and Europe. The chance of endometrial cancer increases with age, with maximum cases diagnosed after menopause.
Endometrial cancer regularly produces symptoms at noticeably early levels, so the disease is normally identified early. The overall survival rate is pretty good, as an instance, inside the US, the five-year relative survival rate (which compares the five-year survival of human beings with cancers to the survival of others of equal age who don't have cancers) for all endometrial cancer cases is around 71%.
Key trends and restrains High incidence of cancers and rising call for safe and effective medicinal drugs can be attributed to the growth of this market. The regulatory bodies are supporting the increase in the global marketplace by expanding funding, designations and grants for rushing up the drug development system.
Diagnosis of endometrial cancer at an early degree is achieved by way of ordinary pelvic examination. However, when cancers reach a superior stage, biopsy or Pap smear is used as a diagnostic technique. The remedy alternatives available to the patients are chemotherapy, radiation remedy, and surgical procedure, presenting maximum possibilities to the worldwide endometrial cancers therapeutics market.
Excessive prevalence and recurrence of endometrial cancers after treatment with chemotherapy is the important riding factor driving the revenue of the market. Growing occurrence of weight problems in women aged 50 years or above is also contributing to the increase. Other than this, protection concerns after chemotherapy, hormone therapy, and radiation treatment limit the development of the endometrial cancer market.
Demographically The market is segmented geographically into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominates the market with 34% market share. The overall market is to witness a growth of CAGR of 5.45% and a forecasted market value of USD 22.68 billion by 2021.
Key market players in the global Uterine Cancer Therapeutics market such as Abbott Laboratories (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), Becton, Dickinson and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline Plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Siemens Healthcare GmbH (Germany), and Takeda Pharmaceutical Company Ltd. (Japan).
The scope of the report provides: • The evaluation of the current market for your product or services and the future implications of the market • Addresses the opportunities by better understanding the market through size estimates and growth rate analysis to forecast the market for the future • Extensive segmentation to understand the dynamics of market at a very granular level by splitting down the market to the smallest segment • Addresses the key market dynamics involving the drivers, restraints and challenges with an aim of providing insights for gaining market share • The factors responsible for the shaping of the industry as it is as a result of competitive environment is analyzed through Porter’s Five Forces • The effects of political, economic, social, technological, legal and environmental factors on the industry is analyzed through PESTLE analysis to better understand the aspects of strategic management required to comply with the exogenous and endogenous factors • Strategic evaluation of the key players to gain insights of their performance allowing access to their product portfolio, financial performance and the strengths of their business strategic developments • Comparative study of the firms across the industry measuring their performances based on market share and recent activities in order to achieve competitive intelligence • Equip you with the information providing with the investment opportunities in the industry Looking for more? If you are in need of a specific research study, we have an expertise in undertaking a customized study and will aid to meet your research requirement to the fullest.
About MarketDataForecast: Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions.
Contact Info: Name: Mr. Abhishek Shukla Email: abhishek@marketdataforecast.com Organization: MarketDataForecast™ Address: 2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India. Phone: +1-888-702-9626
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
